Using nanoparticles to improve gene therapy for blood stem cells
CD90-targeted nanoparticles for in vivo hematopoietic stem cell gene therapy
This study is exploring a new way to use tiny particles to change your own blood stem cells right in your body, making gene therapy easier and safer for people with genetic blood disorders who struggle to find donors for transplants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11048496 on NIH RePORTER |
What this research studies
This research focuses on developing a method to genetically modify a patient's own blood stem cells using nanoparticles, which could allow for safer and more accessible gene therapy. Currently, many patients with genetic blood disorders face challenges in finding suitable donors for stem cell transplants, and existing gene therapy methods require complex facilities. By enabling in vivo gene therapy, this approach aims to simplify the process and reduce the need for specialized infrastructure. The research will utilize advanced techniques to ensure that the nanoparticles effectively target and modify the blood stem cells directly within the patient's body.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with genetic blood disorders who do not have a suitable HLA-matched donor for stem cell transplantation.
Not a fit: Patients with non-genetic blood disorders or those who have access to suitable HLA-matched donors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more accessible treatment option for patients with genetic blood diseases.
How similar studies have performed: While gene therapy for blood disorders has shown promise, the specific approach of using nanoparticles for in vivo modification is relatively novel and has not been extensively tested.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Kiem, Hans-Peter — Fred Hutchinson Cancer Center
- Study coordinator: Kiem, Hans-Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.